Ownership
Private
Employees
~10
Therapeutic Areas
Neurology
Stage
Phase 1
Modalities
Small molecule

Mitochon Pharmaceuticals General Information

Lead compound MP101 showed protective effects in preclinical studies including brain volume sparing in Huntington's disease, axonal protection in Multiple Sclerosis, and motor improvement in Rett Syndrome and Parkinson's disease. Phase 1 studies in healthy volunteers initiated in 2016.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

MP101
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Mitochon Pharmaceuticals's pipeline data

Book a demo

Key Partnerships

No partnerships listed

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Mitochon Pharmaceuticals Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Mitochon Pharmaceuticals's complete valuation and funding history, request access »

Mitochon Pharmaceuticals Investors

Ben Franklin Technology Partners of Southeastern PA
Investor Type: Venture Capital
Holding: Minority
Cures Within Reach
Investor Type: Venture Capital
Holding: Minority
YT Angels
Investor Type: Venture Capital
Holding: Minority